Laurie Toich, Assistant Editor

Mid-range levels of phosphate in the blood may reduce the risk of heart attack.

Only 15% of patients with a 20% to 24% risk of breast cancer received a recommended MRI screening.

Less than half of diabetic foot ulcers heal within 1 year.

The FDA created a framework to create safe and effective regenerative medicine products.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.

Sunitinib malate (Sutent) may improve disease-free survival among patients with renal cell carcinoma.

Emicizumab-kxwh is administered as a weekly subcutaneous injection to restore clotting ability in patients with hemophilia.

Emicizumab-kxwh (Hemlibra) demonstrated the ability to reduce bleeding events that require treatment in patients with hemophilia A.

Fulvestrant (Faslodex) plus abemaciclib may improve progression-free survival among patients with advanced or metastatic breast cancer.

Benralizumab is a monoclonal antibody that causes natural killer immune cells to reduce eosinophils.

Benralizumab (Fasenra) demonstrates the ability to significantly deplete eosinophils and could reduce the need for oral steroid use.

The NSS-2 Bridge device reduced opioid withdrawal symptoms more than 31% within 30 minutes of treatment.

Febuxostat (Uloric) could escalate heart-related and all-cause mortality.

Fallopian tube lesions may be the precursor to high-grade serious ovarian carcinoma.

The 2016/2017 H3N2 influenza vaccine was only 30% effective, leaving many vulnerable to infection.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Vestronidase alfa-vjbk (Mepsevii) approved mucopolysaccharidosis type VII, an extremely rare metabolic condition is also known as Sly syndrome.

Vestronidase alfa-vjbk (Mepsevii) approved to treat mucopolysaccharidosis.

The efficacy and safety of an adalimumab biosimilar matched the reference products in switching studies treating plaque psoriasis and rheumatoid arthritis.

Study finds that most clinical trials lack diversity, which could affect known treatment responses.

Exposure to ammonia found to amplify breast cancer cell proliferation.

The same genes may influence asthma, hay fever, and eczema risk.

Mortality risk may be significantly lowered among older women who participate in moderate to vigorous physical activity.

Significant gains have been made against viral hepatitis.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Empagliflozin (Jardiance) reduced the risk of cardiovascular mortality by 43% in patients with type 2 diabetes and peripheral artery disease.